Navigation Links
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Date:2/4/2008

e a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.

L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006.

As previously announced, in the United States the Company continues to work with COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by COG and to respond to other questions in the not approvable letter the Company received from the U.S. Food and Drug Administration (FDA).

L-MTP-PE was granted orphan drug status in the United States in 2001. The new drug application (NDA) for L-MTP-PE was submitted to FDA in October 2006 and was accepted for review in December 2006.

About Osteosarcoma

About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... BETHESDA, Md., Nov. 1, 2011   For the first ... cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review ... approval in 2012. This milestone comes as the largest ... Anaheim, Calif., Nov. 3 – 5, 2011. ...
... the world,s leading provider of centralized expert assessments in ... disorders, announced it has been selected as one of ... NJBIZ, New Jersey,s premiere business news publication, annually identifies ... New Jersey,s most dynamic companies who progressively contribute to ...
Cached Medicine Technology:Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care 2MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... Newport Beach, CA (PRWEB) November 23, 2014 ... founder of American Medical Aesthetics & Wellness was ... Dr. Asher Milgrom, Ph.D. is president and CEO of ... Skincare. Dr. Asher Milgrom received a full scholarship ... Sciences and the Medical School at the University of ...
(Date:11/23/2014)... Syngenta lawsuits are now being investigated ... and agribusinesses that have allegedly incurred significant financial damages ... and Agrisure Duracade, genetically modified (GMO) corn seed ... in China. According to a report from Bloomberg News, ... corn imports. Because China is the third-largest American corn ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3
... of using plant hormones to fight cancer cells. Plant need ... cuttings grow roots. Scientists at the Cancer Research Campaign (CRC), ... kill cancer cells. , Indole ... IAA are added with an enzyme, toxic by products, which ...
... itself by growing new cells after a heart attack. This ... Italy. Dr. Piero Anversa and colleagues of the New York ... called myocytes continued to divide after a heart attack. ... the hearts of 13 people who died within a few ...
... disease, that requires insulin injections daily. Researchers are slowly ... Some medical research centers in the U.S. and Europe ... by transplanting insulin-producing islet cells combined with less toxic ... lives without insulin. , A.M. ...
... size of children's tummies may offer a simple method of ... diabetes at a later age.Among adults, fat around the waist ... studies suggest that it is a better indicator of risk ... ,A large waist is said to be associated ...
... the brain and its function has always left man ... puzzle, some key factors// have been identified that could ... in premature babies and hence help treat prematurity. ... also prevent brain damage repair in neurological diseases like ...
... drinking coffee could decrease the risk of liver cancer.Researchers ... showed self-reported frequency of coffee consumption among more than ... researchers say they found that those who drink coffee ... while those drinking one or more cups a day ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: